J E Zuckerman - Concepedia

Author

J E Zuckerman

Ionis Pharmaceuticals (United States)

Also Known As

J E Zuckerman, J. E. Zuckerman, Joan E. Zuckerman

Publications

907

Citations

H-Index

Concepts

All Affiliations

Ionis Pharmaceuticals (United States)The University of Texas MD Anderson Cancer Center

About

J E Zuckerman is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	254
2	Biochemistry	2	2	91
3	Engineering	1	1	22
4	Health Sciences	1	1	67
5	Biomedical Engineering	1	1	22

J E Zuckerman

Publications

907

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetic properties of several novel oligonucleotide analogs in mice. Stanley T. Crooke, Melissa Graham, J E Zuckerman, Journal of Pharmacology and Experimental Therapeutics	1996	228
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. SN Weber, J E Zuckerman, David G. Bostwick, Journal of Clinical Investigation	1985	217
Phase I Safety and Pharmacokinetic Profile of an Intercellular Adhesion Molecule-1 Antisense Oligodeoxynucleotide (ISIS 2302) J M Glover, Janet M. Leeds, Tim Mant, Journal of Pharmacology and Experimental Therapeutics	1997	136
Effect of acute lung injury on angiotensin converting enzyme in serum, lung lavage, and effusate. Mannfred A. Hollinger, Shri N. Giri, Steven W. Patwell, PubMed Acute Lung InjuryLung InflammationLung AceInflammationClinical Injury	1980	67
Biochemical and structural alterations of hamster lungs in response to intratracheal administration of bleomycin Shri N. Giri, Lester W. Schwartz, Mannfred A. Hollinger, Experimental and Molecular Pathology TracheobronchitisBiochemistryRespiratory ToxicologyMedicinePhysiology	1980	61
Evaluation of antifibrotic drugs in bleomycin-induced pulmonary fibrosis in hamsters. J E Zuckerman, Mannfred A. Hollinger, Shri N. Giri Journal of Pharmacology and Experimental Therapeutics	1980	51
Effect of paraquat on serum angiotensin converting enzyme. Mannfred A. Hollinger, Steven W. Patwell, J E Zuckerman, PubMed InflammationMolecular PharmacologyHypertensionSerum AngiotensinMedicine	1980	39
Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid C. Frank Bennett, J E Zuckerman, Doug Kornbrust, Journal of Controlled Release Pharmaceutical SciencePharmacological StudyBiochemistryMedicineOligonucleotide	1996	30
Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial. A. Ribas, L. Kalinoski, Jeremy D. Heidel, Journal of Clinical Oncology NanoparticlesNanotherapeuticsEngineeringBiomedical EngineeringPolyethylene Glycol	2010	22
Doxorubicin analogs incorporating chemically reactive substituents David Farquhar, Robert Newman, J E Zuckerman, Journal of Medicinal Chemistry	1991	21

Page 1